ERBB2 and breast carcinoma: As above discussed in detail, numerous clinical studies have supported the introduction in therapy and the approval of PIK3 inhibitors and CDK 4/6 inhibitors for the treatment of ER-positive/HER2-negative breast cancers after endocrine-based therapy.